Skip to main content

Table 5 Cost, outcomes and incremental cost effectiveness ratio for combination therapy compared with dutasteride monotherapy

From: A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model

10-year horizon

Total cost US$

Total QALYs

Incremental costs

Incremental QALYs

Incremental cost per QALY gained

 Fixed dose therapy

1450279504.76

18836849.43

594535937.61

401192.00

1481.92

 Dutasteride

855743567.15

18435657.43

   

15-year horizon

     

 Combination

2194123563.22

23890352.46

852086147.24

938291.33

908.13

 Dutasteride

1578867548.20

20879011.27

   
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us